Welcome to our dedicated page for Adagio Medical SEC filings (Ticker: ADGM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Adagio Medical Holdings, Inc. (Nasdaq: ADGM) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures, giving investors structured access to official information about this medical device issuer. Adagio’s filings describe its focus on catheter-based Ultra-Low Temperature Cryoablation (ULTC) technology for cardiac arrhythmias and provide detail on its corporate structure, governance, and capital markets activity.
Through Form 8-K current reports, Adagio furnishes information on material events such as private placement financings, preliminary clinical data releases, and key leadership appointments. For example, recent 8-K filings reference the Securities Purchase Agreement for a private placement of common stock and warrants, the closing of that financing, and press releases announcing acute results from the FULCRUM-VT pivotal IDE study and the completion of enrollment in that trial. Other 8-Ks disclose changes in executive roles, including the expansion of the Chief Business Officer’s responsibilities to include Chief Financial Officer, and the scheduling of the company’s annual meeting.
Adagio’s DEF 14A definitive proxy statement provides additional context on board elections, auditor ratification, executive compensation, security ownership, and the business combination that created Adagio Medical Holdings, Inc. It also outlines stockholder voting procedures and meeting logistics. Periodic reports such as Forms 10-Q and 10-K, when viewed alongside these current reports, give a fuller picture of Adagio’s financial condition and risk disclosures, although they are not reproduced in the text above.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight key terms, clinical and regulatory milestones, and financing structures, helping readers interpret complex documents more quickly. Users can also review filings related to equity issuances and warrant terms, as well as governance documents that frame Adagio’s ongoing reporting obligations as an emerging growth company listed on The Nasdaq Stock Market LLC.
Adagio Medical Holdings announced positive pivotal six‑month results from its -VT IDE trial of the vCLAS ventricular ablation system for treating ventricular tachycardia (VT). The study enrolled 209 patients with structural heart disease and met both safety and effectiveness endpoints, showing 84% freedom from ICD shock and 59% freedom from VT recurrence.
The trial included both ischemic and non‑ischemic cardiomyopathy patients, who achieved equivalent outcomes using an endocardial‑only ablation approach. Major adverse events occurred in 2.4% of patients, including 1.9% peri‑procedural deaths, with only 1.0% adjudicated as possibly device‑related. The company plans to use these data to support an FDA premarket approval application for vCLAS.
Adagio Medical Holdings, Inc. has scheduled its 2026 Annual Meeting of Stockholders for June 16, 2026. Stockholders of record at the close of business on April 24, 2026 will be entitled to receive notice of, and vote at, the meeting.
Stockholder proposals and director nominations must be received by the Company’s Secretary by April 30, 2026 to be considered, including proposals under Rule 14a-8 and notices required by the Company’s bylaws and the SEC’s universal proxy rules.
Adagio Medical Holdings, Inc. reported that the FDA has granted Investigational Device Exemption (IDE) approval to expand its -VT trial to study the next-generation vCLAS Ultra-Low Temperature Ablation (ULTA) Ventricular Ablation System for treating sustained monomorphic ventricular tachycardia. The IDE expansion allows a prospective, single-arm, multi-center sub-study of up to 55 patients with scar-mediated VT in ischemic and non-ischemic cardiomyopathy. The new vCLAS Ultra catheter targets ablation temperatures near -170°C and has shown over 50% reductions in ablation time in pre-clinical models, aiming to deliver deeper lesions, shorter procedure times, and improved usability on Adagio’s established endocardial ULTA platform.
Adagio Medical Holdings, Inc. filed Post-Effective Amendment No. 2 to its Registration Statement (File No. 333-284266) to correct Exhibit 23.4 by replacing an unsigned consent from WithumSmith+Brown, PC with the proper signed consent. The amendment states no other changes to the registration statement or prospectus.
Adagio Medical Holdings, Inc. filed Post-Effective Amendment No. 2 to its Registration Statement (File No. 333-284263) to correct Exhibit 23.4, the consent of its independent registered public accounting firm. The amendment replaces an unsigned consent previously filed and makes no other changes to the registration statement or prospectus.
Adagio Medical Holdings, Inc. filed a Post-Effective Amendment converting its previously effective Form S-1 into a Form S-3 shelf registration to permit resale of up to 31,818,652 shares of Common Stock by selling stockholders, comprised of Registration Delay Shares, Convertible Note Shares and Warrant Shares.
The prospectus states the Company will not receive proceeds from resales except up to an aggregate of $14.4 million if all warrants are exercised for cash. Shares outstanding were 22,210,459 as of March 23, 2026; pro forma assuming full conversion/exercise would be 53,955,778. The filing notes the market price was $1.15 per share as of March 31, 2026 and warns that resale or perceived resale could materially pressure the share price.
Adagio Medical Holdings, Inc. amends its registration statement to convert the prior Form S-1 into a Form S-3 shelf registration and files a preliminary prospectus registering up to 67,963,695 shares of Common Stock for resale by the named selling stockholders.
The filing states that no additional securities are being registered under this amendment and that the company will not receive proceeds from the resale of the registered shares, except that it would receive cash proceeds up to approximately $96.9 million, assuming full cash exercise of outstanding warrants. Shares outstanding were 22,210,459 as of March 23, 2026, and the prospectus shows a pro forma outstanding share count of 79,175,666 assuming conversion/exercise of listed instruments.
Adagio Medical Holdings, Inc. registers up to 67,963,695 shares of Common Stock for resale by the selling stockholders named in the prospectus supplement. The registration encompasses multiple components including PIPE Shares, Pre-Funded Warrant Shares, PIPE Warrant Shares, Convertible Note Shares and various sponsor‑ and option‑related shares.
The supplement incorporates the company’s Annual Report on Form 10‑K for the fiscal year ended December 31, 2025 and states a last reported sales price of $1.24 per share on March 26, 2026. Shares outstanding were 22,210,459 as of March 23, 2026.